文献速递预防保健、筛查与疫苗常见症状与未分化疾病

评估与管理过敏史:新型mRNA疫苗接种的队列研究

Assessment and management of allergy history with a novel mRNA vaccine.
PubMed 文献 · Ann Fam Med · 2022-04-01

某城市三级医院对7000余名接种首剂mRNA新冠疫苗的员工开展队列研究,约10%有过敏反应史。接种后至少观察15分钟,发现3例首剂即发速发型过敏反应和50余例即发过敏超敏反应,未发现性别、年龄或病史可预测这些反应。

要点

  • 约10%接种者有过敏反应史,但严重过敏史者较少。
  • 首剂mRNA疫苗接种后观察到3例即发速发型过敏反应。
  • 共50余例即发过敏超敏反应,未发现性别、年龄或病史的预测模式。

核心结论

  • mRNA新冠疫苗首剂接种可安全实施,但存在即发速发型过敏反应和即发过敏超敏反应,且未发现性别、年龄或病史的预测模式。

主要发现

  • 共服务超过7000人,约10%有过敏反应史,有药物或疫苗速发型过敏反应史者较少。
  • 观察到3例首剂mRNA疫苗即发速发型过敏反应,以及超过50例即发过敏超敏反应。
  • 未观察到性别、年龄或病史可预测这些反应。

关键数值与推荐

  • 每名接种者观察至少15分钟,所有反应由等待区监督医生复核。
  • 工作协议持续追踪接种、过敏史、观察到的反应及制定的照护计划(判定mRNA疫苗过敏或正常疫苗反应)。

临床怎么用

  • 接种mRNA疫苗时应保证至少15分钟观察,并由医生复核即发反应。
  • 应记录过敏史和超敏反应史,但不应仅凭性别、年龄或病史预测即发过敏反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Tertiary care hospital provided onsite COVID-19 vaccine roll out as a work benefit for all care team members with medically supervised waiting period at the time of the distribution of the first round of the novel mRNA COVID-19 vaccines. Little was known about the immediate hypersensivity reactions or what might predispose to cross reactivity. OBJECTIVE: We developed a working protocol to continuously track the vaccines administered, the patient history of allergy and hypersensistivity, the reactions observed and the care plan developed (determination of allergy to mRNA vaccines or normal vaccine response). Continuous process improvement allowed us to change protocols as the CDC developed guidance. Every patient was observed for at least 15 minutes and every reaction was reviewed by a physician supervising the waiting area. We aimed to determine if there were predictors of adverse, immediate reaction to the vaccine and to assess prevalence of risk factors (history of allergy to polyethylene Glycol or polysorbate; allergy to other injectable medication or vaccines; hypersensitivity to multiple substances). STUDY DESIGN: Cohort study of all employees who received a first mRNA COVID-19 vaccine between December 16 and January 7th. Descriptive statistics were developed with demographic and medical history recorded, reactions noted and treatment given. SETTING OR DATASET: Tertiary care hospital in urban area. POPULATION STUDIED: Employees who received an mRNA COVID-19 vaccine. INTERVENTION/INSTRUMENT: Clinical records from employee vaccine clinic. OUTCOME MEASURES: Record of immediate response, determination of allergy. RESULTS: We served over 7000 individuals with approximately 10% having a history of anaphylactic reaction. We had fewer with history of anaphylaxis to medications or vaccines. We delivered these vaccines safely, and observed three cases of immediate anaphylaxis on first dose of mRNA and over 50 cases of immediate allergic hypersensitivity. We did not see any patterns that predicted these reactions (gender, age or medical history). EXPECTED OUTCOMES: We used this data to inform our employee health vaccination campaign and to inform the health system as strategies and safety protocols for vaccination of the population were developed.

来源:Ann Fam Med,查看原文。版权归原作者所有。

引用

  1. Holt C, Butler J, Sharp K, et al. Assessment and management of allergy history with a novel mRNA vaccine. Ann Fam Med. 2022. PMID: 35881510. doi:10.1370/afm.20.s1.3135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。